Trial record 1 of 1 for:    ACOSOG Z5041
Previous Study | Return to List | Next Study

Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

This study is currently recruiting participants.
Verified February 2013 by National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: August 12, 2008
Last updated: February 13, 2013
Last verified: February 2013

August 12, 2008
February 13, 2013
April 2009
October 2013   (final data collection date for primary outcome measure)
Overall survival at 2 years [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00733746 on Archive Site
  • Resection rate [ Designated as safety issue: No ]
  • Relapse/progression-free survival [ Designated as safety issue: No ]
  • Adverse event profile [ Designated as safety issue: Yes ]
  • Response rate [ Designated as safety issue: No ]
  • Molecular and genetic profiles [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these drugs after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well gemcitabine and erlotinib work when given before and after surgery in treating patients with pancreatic cancer that can be removed by surgery.



  • To estimate the proportion of patients with resectable adenocarcinoma of the pancreas alive at 2 years from the date of study registration after treatment with neoadjuvant and adjuvant gemcitabine hydrochloride and erlotinib hydrochloride plus pancreatectomy.


  • To determine the resection rate (defined as the fraction of patients who proceed to planned surgery with removal of primary tumor [R0/R1]) after neoadjuvant treatment with gemcitabine hydrochloride and erlotinib hydrochloride.
  • To estimate the time to disease progression/relapse in these patients.
  • To evaluate the rate of R0, R1, and R2 resections in these patients.
  • To evaluate the toxicity profile and feasibility of this regimen in these patients.
  • To evaluate response rates in patients treated with this regimen.
  • To identify molecular predictors of response to this regimen.
  • To identify genetic profiles of pancreatic adenocarcinoma that may be associated with response to neoadjuvant therapy.

OUTLINE: This is a multicenter study.

  • Neoadjuvant therapy:Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 29, 36, and 43 and oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity.
  • Surgery:At 3-6 weeks after completion of neoadjuvant therapy, patients undergo pancreaticoduodenectomy.
  • Adjuvant therapy:Beginning 5-10 weeks after surgery, patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in neoadjuvant therapy.

Patients undergo blood and tumor tissue sample collection for correlative laboratory studies. Studies include assessment of epithelial-mesenchymal transition (EMT) markers, analysis of EGFR intron 1 polymorphism, and identification of genetic profiles by RNA analysis.

After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 2 years.

Phase 2
Allocation: Non-Randomized
Masking: Open Label
Primary Purpose: Treatment
Pancreatic Cancer
  • Drug: erlotinib hydrochloride
  • Drug: gemcitabine hydrochloride
  • Genetic: RNA analysis
  • Genetic: gene expression analysis
  • Genetic: polymorphism analysis
  • Other: laboratory biomarker analysis
  • Procedure: adjuvant therapy
  • Procedure: neoadjuvant therapy
  • Procedure: therapeutic conventional surgery
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
October 2013   (final data collection date for primary outcome measure)


  • Histologically or cytologically confirmed adenocarcinoma of the pancreatic head or uncinate process

    • No tumors of the pancreatic neck, body, or tail
    • No evidence of neuroendocrine tumors, duodenal adenocarcinoma, or ampullary adenocarcinoma
  • Localized, potentially resectable* tumor by chest x-ray or CT scan and abdominal CT scan or MRI, as defined by the following:

    • No evidence of tumor extension to the celiac axis, hepatic artery, or superior mesenteric artery
    • No evidence of tumor encasement or occlusion of the superior mesenteric vein (SMV) or the SMV/portal vein confluence
    • No evidence of visceral or peritoneal metastases NOTE: *Patients with borderline resectable or marginally resectable pancreatic cancer are not eligible.


  • ECOG or Zubrod performance status 0-1
  • WBC ≥ 2,000/mm³
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Total bilirubin ≤ 2.5 mg/dL
  • ALT and AST ≤ 2.5 times upper limit of normal
  • Albumin ≥ 3.2 g/dL
  • Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min
  • Baseline weight loss ≤ 15% of premorbid weight
  • No active infection requiring intravenous antibiotics
  • No other malignancy within the past 5 years except for nonmelanoma skin cancer or in situ cancer
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


  • No prior EGFR-targeted therapy
  • No prior therapy for pancreatic cancer
  • No other concurrent investigational or commercial agents or therapies for pancreatic cancer
18 Years and older
Not Provided
United States,   Canada
CDR0000609871, ACOSOG-Z5041
Not Provided
David M. Ota, American College of Surgeons Oncology Group
American College of Surgeons
National Cancer Institute (NCI)
Study Chair: Peter W.T. Pisters, MD M.D. Anderson Cancer Center
National Cancer Institute (NCI)
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP